Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research

Changes in perioperative C-reactive protein levels in patients with rheumatoid arthritis undergoing total knee arthroplasty in the biologic era
In conclusion, serum CRP levels increased rapidly after TKA and peaked on postoperative days 3-4, followed by a return to preoperative levels by postoperative day 14 in patients with RA. Obesity and the use of glucocorticoids were independently associated with changes in CRP levels.PMID:35967944 | PMC:PMC9350574 | DOI:10.18999/nagjms.84.2.286 (Source: Nagoya Journal of Medical Science)
Source: Nagoya Journal of Medical Science - August 15, 2022 Category: International Medicine & Public Health Authors: Kenji Kishimoto Shuji Asai Nobunori Takahashi Kenya Terabe Yasumori Sobue Tsuyoshi Nishiume Mochihito Suzuki Naoki Ishiguro Toshihisa Kojima Source Type: research

Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab
We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.PMID:35970533 | DOI:10.3899/jrheum.220128 (Source: J Rheumatol)
Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Yuhei Ito Hiroki Nakahara Ayako Nakajima Source Type: research

Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152 (Source: J Rheumatol)
Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research

Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab
We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.PMID:35970533 | DOI:10.3899/jrheum.220128 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - August 15, 2022 Category: Rheumatology Authors: Yuhei Ito Hiroki Nakahara Ayako Nakajima Source Type: research

Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research

Changes in perioperative C-reactive protein levels in patients with rheumatoid arthritis undergoing total knee arthroplasty in the biologic era
In conclusion, serum CRP levels increased rapidly after TKA and peaked on postoperative days 3-4, followed by a return to preoperative levels by postoperative day 14 in patients with RA. Obesity and the use of glucocorticoids were independently associated with changes in CRP levels.PMID:35967944 | PMC:PMC9350574 | DOI:10.18999/nagjms.84.2.286 (Source: Nagoya Journal of Medical Science)
Source: Nagoya Journal of Medical Science - August 15, 2022 Category: International Medicine & Public Health Authors: Kenji Kishimoto Shuji Asai Nobunori Takahashi Kenya Terabe Yasumori Sobue Tsuyoshi Nishiume Mochihito Suzuki Naoki Ishiguro Toshihisa Kojima Source Type: research

Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab
We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.PMID:35970533 | DOI:10.3899/jrheum.220128 (Source: J Rheumatol)
Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Yuhei Ito Hiroki Nakahara Ayako Nakajima Source Type: research

Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152 (Source: J Rheumatol)
Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research

Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab
We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.PMID:35970533 | DOI:10.3899/jrheum.220128 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - August 15, 2022 Category: Rheumatology Authors: Yuhei Ito Hiroki Nakahara Ayako Nakajima Source Type: research

Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research

Changes in perioperative C-reactive protein levels in patients with rheumatoid arthritis undergoing total knee arthroplasty in the biologic era
In conclusion, serum CRP levels increased rapidly after TKA and peaked on postoperative days 3-4, followed by a return to preoperative levels by postoperative day 14 in patients with RA. Obesity and the use of glucocorticoids were independently associated with changes in CRP levels.PMID:35967944 | PMC:PMC9350574 | DOI:10.18999/nagjms.84.2.286 (Source: Nagoya Journal of Medical Science)
Source: Nagoya Journal of Medical Science - August 15, 2022 Category: International Medicine & Public Health Authors: Kenji Kishimoto Shuji Asai Nobunori Takahashi Kenya Terabe Yasumori Sobue Tsuyoshi Nishiume Mochihito Suzuki Naoki Ishiguro Toshihisa Kojima Source Type: research

Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab
We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.PMID:35970533 | DOI:10.3899/jrheum.220128 (Source: J Rheumatol)
Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Yuhei Ito Hiroki Nakahara Ayako Nakajima Source Type: research

Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152 (Source: J Rheumatol)
Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research

Development of Pulmonary Alveolar Proteinosis in a Patient With Adult-Onset Still Disease Treated With Tocilizumab
We report a patient with systemic adult-onset Still disease (AOSD) who developed anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive pulmonary alveolar proteinosis (PAP) while using tocilizumab (TCZ), diagnosed by milky white bronchoalveolar lavage fluid (BALF; Figure 1). To our knowledge, this is the first case of PAP in AOSD.PMID:35970533 | DOI:10.3899/jrheum.220128 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - August 15, 2022 Category: Rheumatology Authors: Yuhei Ito Hiroki Nakahara Ayako Nakajima Source Type: research